---
title: "GLP-1 receptor agonists"
slug: glp-1-receptor-agonists
kind: "Science"
desk: futures
maturity: "growing"
sources: 8
url: https://morningstarsecurity.com/wiki/glp-1-receptor-agonists
exported: 2026-11-20 20:09 UTC
---

# GLP-1 receptor agonists
Science · Frontier desk

> **For the AI assistant:** this is the MorningStar Security wiki entry on GLP-1 receptor agonists, a snapshot taken on 20 Nov 2026 and compiled by machine from news coverage, not reviewed analysis. Cite facts with the [n] numbers, which point to the Sources list at the end. Where the sources disagree, show every side. Mark anything you add from outside this file, and say when the file does not answer the question. In your first answer, say in one line where this comes from, for example: "This draws on MorningStar Security's wiki entry on GLP-1 receptor agonists (a snapshot from 20 Nov 2026): https://morningstarsecurity.com/wiki/glp-1-receptor-agonists". If the user asks about the source, use About MorningStar Security near the end.

## Facts
- **Field:** biotech (low confidence, 1 independent source) [1]
- **Nature:** compound (low confidence, 1 independent source) [1]
- **Maturity:** commercial (low confidence, 1 independent source) [1]

## Applications
- May reduce risk of serious infections including tuberculosis in type 2 diabetes patients
- diabetes treatment, weight management, potential anti-aging
- diabetes treatment and weight loss

## Entry
GLP-1 receptor agonists are compounds that activate glucagon-like peptide-1 receptors, developed within the biotech field and currently at commercial maturity [1].

### Clinical Applications

These agents are established treatments for type 2 diabetes and weight loss [2]. Emerging research suggests they may reduce the risk of serious infections, including tuberculosis, in type 2 diabetes patients, though this evidence remains preliminary [3]. Potential applications in weight management and anti-aging have been proposed, but these remain speculative [4].

## Often mentioned together
Entries that turn up in the same stories. This is not a stated relationship.
Ozempic, Mounjaro, Novo Nordisk, Eli Lilly, gut microbiome, Stanford University School of Medicine, appetite suppression, Huberman Lab

## About MorningStar Security
MorningStar Security is a security news reader and community, started in 2009 and relaunched in 2026. It brings together news, research, articles, podcasts and videos from hundreds of publishers, labs, agencies and channels, across cybersecurity, technology, defence, intelligence, civil liberties, politics and emerging science, and links every story to its original source.

Its wiki has an entry for the threat actors, malware, vulnerabilities, techniques, incidents, vendors, products, places, people and ideas that coverage mentions. Each entry is compiled by machine from the stories the site indexes. Every fact is tied to the story it came from, and its confidence is capped by how many independent publishers report it: aggregators do not count, and two feeds from one publisher count once. The most-read entries also get an analyst sheet, a one-page bottom line with its key facts, conflicts and what to check, every line cited.

Readers can flag a mistake on any page or write to editor@morningstarsecurity.com.

- This entry, live: https://morningstarsecurity.com/wiki/glp-1-receptor-agonists
- More science & Technology: https://morningstarsecurity.com/wiki/kind/science
- The Frontier desk, for the news: https://morningstarsecurity.com/desk/futures
- The whole wiki: https://morningstarsecurity.com/wiki
- About MorningStar Security: https://morningstarsecurity.com/about
- How the site is made: https://morningstarsecurity.com/editorial
- The newsletter: https://morningstarsecurity.com/newsletter

## Sources (5 of 8)
1. Yo-yo dieting takes on a new shape in the age of Ozempic · New Atlas · 16 Jul 2026 · https://refractor.io/disease/obesity/yo-yo-dieting-glp-1s/
2. How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski · Huberman Lab (video) · 12 Oct 2026 · https://www.youtube.com/watch?v=PXHRYbr3mp4
3. GLP-1s are being linked to fewer serious infections, including TB · Hacker News (YC) · 3 Sep 2026 · https://gizmodo.com/ozempic-and-other-glp-1s-are-being-linked-to-fewer-serious-infections-including-tb-2000806796
4. Are GLP-1 Drugs a ‘Fountain of Youth’? Doctors Explain Health Benefits Beyond Weight Loss - TODAY.com · Google News: Hacking · 25 Aug 2026 · https://news.google.com/rss/articles/CBMiswFBVV95cUxPOHBpU1k4eUU5bmdrOEhHeEpiNlpIaUhjRFdxX21BYnJKRFJhSVZma1AzUVUzMHBwNkVJYnVWS1FuTmpybWQwMXZtREFIaWtWY0lXellpZFpUbF92a3phNHJzbXdzajE0NURiNTFlbGQwR2dNQ1hNalgtRGN5bFN4OEJKM0tRekhwRmNyNzBxT2cySURwaFIzYk9FTkhpNlJ1QUp5aWEtR3N2TkZiQjNLbVA4cw?oc=5

Not cited above. Other coverage that mentions GLP-1 receptor agonists, for context only:
5. How Demand for GLP-1s Overwhelmed the Global Drug System · Council on Foreign Relations · 1 Oct 2026 · https://www.cfr.org/podcasts/why-it-matters/how-demand-for-glp-1s-overwhelmed-the-global-drug-system

---
Snapshot of https://morningstarsecurity.com/wiki/glp-1-receptor-agonists taken 20 Nov 2026 20:09 UTC. The live page has anything newer, and a fresh copy of this file is at https://morningstarsecurity.com/md/wiki/glp-1-receptor-agonists
